Literature DB >> 24356412

The role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer.

Valentin Kolev1, Elena B Pereira, Myron Schwartz, Umut Sarpel, Sasan Roayaie, Daniel Labow, Mazdak Momeni, Linus Chuang, Peter Dottino, Jamal Rahaman, Konstantin Zakashansky.   

Abstract

OBJECTIVE: The aim of this study is to determine the role of liver metastatectomy in the morbidity and survival of patients with recurrent ovarian carcinoma.
METHODS: We retrospectively reviewed the records of all patients who had undergone hepatic resection for liver metastases from ovarian carcinoma at the time of cytoreductive surgery at our institution from 1988 to 2012. The Kaplan-Meier method was used for survival analysis. A total of 76 patients met the inclusion criteria and had undergone liver resection as part of cytoreductive surgery for ovarian carcinoma during the study period. Of these 76 patients, 27 underwent liver resection at the time of secondary cytoreduction, and these patients that are the focus of this analysis.
RESULTS: Median overall survival for the study group from the time of diagnosis to the last follow-up or death was 56 months (range, 12-249 months). Twenty died of the disease with an overall median survival of 12 months from the time of the liver resection (2-190 months), and 7 patients were alive with the disease at the time of the last follow-up. Based on Kaplan-Meier survival analysis, the factors associated with the longest survival after the liver resection (2-190 months) were the interval from the primary surgery of less than 24 months versus more than 24 months (P = 0.044) and secondary cytoreduction to residual disease of less than 1 cm (P = 0.014).
CONCLUSIONS: Based on our analysis of a single institution's series of ovarian cancer patients with hepatic metastasis, liver resection is feasible and safe and should be considered as an option in selected patients at the time of secondary cytoreduction.

Entities:  

Mesh:

Year:  2014        PMID: 24356412     DOI: 10.1097/IGC.0000000000000026

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

Review 1.  Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.

Authors:  Shaun Hiu; Andrew Bryant; Ketankumar Gajjar; Patience T Kunonga; Raj Naik
Journal:  Cochrane Database Syst Rev       Date:  2022-08-30

Review 2.  Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer.

Authors:  Maria Luisa Gasparri; Giovanni Grandi; Daniele Bolla; Beat Gloor; Sara Imboden; Pierluigi Benedetti Panici; Michael D Mueller; Andrea Papadia
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-11       Impact factor: 4.553

Review 3.  Surgical management of lung, liver and brain metastases from gynecological cancers: a literature review.

Authors:  Neville F Hacker; Archana Rao
Journal:  Gynecol Oncol Res Pract       Date:  2016-06-17

Review 4.  Role of surgical resection for non-colorectal non-neuroendocrine liver metastases.

Authors:  Nobuyuki Takemura; Akio Saiura
Journal:  World J Hepatol       Date:  2017-02-18

5.  Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit.

Authors:  Nicolae Bacalbasa; Simona Dima; Vladislav Brasoveanu; Leonard David; Irina Balescu; Raluca Purnichescu-Purtan; Irinel Popescu
Journal:  World J Surg Oncol       Date:  2015-08-05       Impact factor: 2.754

6.  Liver Resection as Part of Cytoreductive Surgery for Ovarian Cancer.

Authors:  Jorge Luna-Abanto; Luis García Ruiz; Jheff Laura Martinez; Manuel Álvarez Larraondo; Vladimir Villoslada Terrones
Journal:  J Gynecol Surg       Date:  2020-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.